Type 2 diabetes prevention

[Guest guest]

Type 2 diabetes prevention

Wonderful news in the world of diabetes research from the Lancet this morning. The two drugs rosiglitazone and metformin showed to be effective in preventing type 2 diabetes in persons with impaired glucose tolerance.

In my family alone there are 3 type two diabetics and one juvenile diabetic.

..

This may be of interest to anyone living with diabetes:

..

My niece (juvenile diabetic) is insulin-dependent , her blood sugar levels are difficult to keep in target range . When she was younger her glucose was often to high, now its to low. Unfortunately she doesn't have any warning when this develops and often found herself in dangerous circumstances. She now has a "Diabetic Alert Dog ", which is trained to identify, and alert her by the subtle scent changes in hypoglycemia (low glucose). How wonderful this dog has given her a near normal lifestyle.

See Links;

,

http://www.diabeticalertdog.com/links.html

http://www.dogs4diabetics.com/ http://www.diabeticalertdog.com/

The Lancet, Early Online Publication, 3 June 2010doi:10.1016/S0140-6736(10)60746-5

Cite or Link Using DOI

Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.

Original TextProf Bernard Zinman MD a b , Prof B MD c, Jan Neuman MSc a, Prof Hertzel C Gerstein MD d, Ravi R Retnakaran MD a, Janet Raboud PhD e f, Ying Qi MSc a, JG Hanley PhD a g

SummaryBackgroundThe evolving epidemic of type 2 diabetes has challenged health-care providers to assess the safety and efficacy of various diabetes prevention strategies.

The CANOE (CAnadian Normoglycemia Outcomes Evaluation) trial investigated whether low-dose combination therapy would affect development of type 2 diabetes.

MethodsIn this double-blind, randomised controlled trial undertaken in clinics in Canadian centres, 207 patients with impaired glucose tolerance were randomly assigned to receive combination rosiglitazone (2 mg) and metformin (500 mg) twice daily or matching placebo for a median of 3·9 years (IQR 3·0—4·6). Randomisation was computer-generated in blocks of four, with both participants and investigators masked to treatment allocation. The primary outcome was time to development of diabetes, measured by an oral glucose tolerance test or two fasting plasma glucose values of 7·0 mmol/L or greater. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00116932.

Findings103 participants were assigned to rosiglitazone and metformin, and 104 to placebo; all were analysed. Vital status was obtained in 198 (96%) participants, and medication compliance (taking at least 80% of assigned medication) was 78% (n=77) in the metformin and rosiglitazone group and 81% (n=80) in the placebo group.

Incident diabetes occurred in significantly fewer individuals in the active treatment group (n=14 [14%]) than in the placebo group (n=41 [39%]; p less then 0-0001). p="0·0002 32"more thenIQR −2·38 to −0·08) and remained unchanged with rosiglitazone and metformin treatment (−0·39, −1·30 to 0·84; p=0·0006 between groups). The change in β-cell function, as measured by the insulin secretion-sensitivity index-2, did not differ between groups (placebo −252·3, −382·2 to −58·0 vs rosiglitazone and metformin −221·8, −330·4 to −87·8; p=0·28). We recorded an increase in diarrhoea in participants in the active treatment group compared with the placebo group (16 [16%] vs 6 [6%]; p=0·0253).

InterpretationLow-dose combination therapy with rosiglitazone and metformin was highly effective in prevention of type 2 diabetes in patients with impaired glucose tolerance, with little effect on the clinically relevant adverse events of these two drugs.

FundingGlaxoKline.

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60746-5/fulltext

http://Hepatitis Cnewdrugs.blogspot.com/2010/06/type-2-diabetes-prevention.html